1-5 of 5
Sarah Leong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, Mittal Shah, Toby Batten, David Tucker, Bryson Pottinger, Shankaranarayana Paneesha, Dima El-Sharkawi, Toby A. Eyre, Ho Pui Jeff Lam, Jiexin Zheng, Sarah Cook, David Granger, David Ahern, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani
Journal: Blood
Blood (2023) 142 (Supplement 1): 329.
https://doi.org/10.1182/blood-2023-188607
Published: 2023
Journal Articles

First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, David Tucker, Bryson Pottinger, Shankara Paneesha, Dima El-Sharkawi, Toby A. Eyre, Toby Batten, Mittal Shah, Sarah Cook, David Granger, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani
Journal: Blood
Blood (2022) 140 (Supplement 1): 4162–4163.
https://doi.org/10.1182/blood-2022-169658
Published: 2022
Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E Bröske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Journal: Blood
Blood (2022) 140 (Supplement 1): 397–399.
https://doi.org/10.1182/blood-2022-157988
Published: 2022
Journal Articles

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

Henry Wood, Christianne Bourlon, Austin Kulasekararaj, Albert Borg, Jiri Pavlu, Patrick Elder, David C Taussig, Scott Veitch, Steven Knapper, Jad Othman, Richard Dillon, James Aries, Emily Mitchell, Faisal Basheer, Steven Leak, Vidhya Murthy, Joe W Cross, Priyanka Mehta, Manish Jain, Anjum Khan, Ho Lam, Sarah Leong, Jenny O'Nions, Charles Craddock, Victoria Potter, Mhairi Copland, Pramila Krishnamurthy
Journal: Blood
Blood (2022) 140 (Supplement 1): 9016–9018.
https://doi.org/10.1182/blood-2022-167097
Published: 2022
Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Martin Hutchings, Caroline Hasselbalch Riley, Ann-Marie E Bröske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10137–10139.
https://doi.org/10.1182/blood-2022-158146
Published: 2022